TA, B., MW, M., LB, L., JM, O., DM, M., RE, F., . . . RA, S. (2021). Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia. Dove Medical Press.
Chicago Style (17th ed.) CitationTA, Berger, Manry MW, Lindsell LB, Osher JM, Miller DM, Foster RE, Riemann CD, Petersen MR, and Sisk RA. Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia. Dove Medical Press, 2021.
MLA (8th ed.) CitationTA, Berger, et al. Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia. Dove Medical Press, 2021.
Warning: These citations may not always be 100% accurate.